[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimers-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimers-disease":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,47,80,112,134,161,189,207,233,257,285,308,326,349,383,412,437,448,473,501,529,556,585,606,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053743","dominantly-inherited-alzheimer-network-dian-100053743",false,"NCT00869817","Dominantly Inherited Alzheimer Network (DIAN)","DIAN","Inclusion Criteria:\n\n* Written informed consent obtained from participant and collateral source prior to any study-related procedures.\n* Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.\n* Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.\n* Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.\n* Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.\n\nExclusion Criteria:\n\n* Under age 18\n* Medical or psychiatric illness that would interfere in completing initial and follow-up visits\n* Requires nursing home level care\n* Has no one who can serve as a study informant",true,"ALL","18 Years",{"count":21,"type":22},700,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.",[26],"Alzheimer's Disease",[28,29,30,31,32,33],"Alzheimer's disease","antecedent biomarkers","Amyloid Precursor Protein (APP) mutation","presenilin I (PS1) mutation","presenilin 2 (PS2) mutation","Autosomal Dominant Alzheimer's Disease","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":4},"2009-01",{"date":42,"type":22},"2027-07",{"name":44,"class":45},"Washington University School of Medicine","OTHER",26,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100605979","phase-3-a-study-of-trontinemab-in-participants-with-early-symptomatic-alzheimers-disease-100605979","NCT07169578","A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)","TRONTIER 1","Inclusion Criteria:\n\n* Willingness and ability to complete all aspects of the study (including MRI, clinical genotyping, and PET imaging or CSF as applicable) for the duration of the study. The participant should be capable of completing assessments either alone or with the help of the study partner\n* Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)\n* Evidence of AD pathological process, as confirmed on amyloid PET scan. A CSF tau181\u002FAβ42 ratio may be used as an alternative option if amyloid PET is not available\n* Probable AD dementia or MCI due to AD, also known as an Alzheimer's clinical syndrome clinical Stage 3 or Stage 4\n* Screening MMSE score ≥ 22 and CDR-GS of 0.5 or 1.0\n* Participant- and\u002For Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening\n* A Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) score of 85 or order\n* Availability of a \"study partner\" as defined by the protocol\n\nExclusion Criteria:\n\n* Any evidence of a condition other than AD that may affect cognition\n* History or presence of clinically significant cerebrovascular disease\n* History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma\n* History or presence of clinically significant intracranial mass\n* MRI evidence of significant cerebral abnormalities or inability to tolerate MRI procedures or contraindication to MRI\n* Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments\n* History of malignancy with the following exceptions: if considered to be cured; malignancies with a negligible risk of metastasis or death","50 Years","90 Years",{"count":58,"type":22},800,"INTERVENTIONAL",[61],"PHASE3","The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \\[MCI\\] to mild dementia due to AD).",[64],"Alzheimers Disease",[66,67,68],"Early Alzheimers Disease","Mild Cognitive Impairment","Mild Dementia","2026-07-01",{"date":71,"type":38},"2026-07-02",{"date":73,"type":38},"2025-09-17",{"date":75,"type":22},"2028-06-07",{"name":77,"class":78},"Hoffmann-La Roche","INDUSTRY",143,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":59,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100392965","phase-1-pet-imaging-of-cyclooxygenases-in-neurodegenerative-brain-disease-100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.","99 Years",{"count":89,"type":22},184,[91],"PHASE1","Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[94,95,26,96,67],"Parkinson's Disease","Dementia","ALS",[98,99,100,95,101,96,102],"PET Imaging","PD","Inflammation","Cyclooxygenase-2","MCI",{"date":71,"type":38},{"date":105,"type":38},"2021-08-17",{"date":107,"type":22},"2030-10-03",{"name":109,"class":110},"National Institute of Mental Health (NIMH)","NIH",1,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":59,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100611004","phase-1-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-ro7812653-in-participants-with-early-symptomatic-alzheimers-disease-ead-100611004","NCT07234942","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease","Inclusion Criteria:\n\n* Probable AD dementia (consistent with National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia) \\[McKhann et al 2011\\] or Mild Cognitive Impairment (MCI) due to AD (consistent with the NIA-AA core clinical criteria for mild cognitive impairment due to AD) \\[Albert et al 2011\\]).\n* Willingness and ability to complete all aspects of the study. The participant should be capable of completing assessments either alone or with the help of the study partner.\n* Fluency in the language of the tests used at the study site.\n* Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted).\n* If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 8 weeks prior to screening and until randomization is required.\n* Agreement not to participate in other research studies for the duration of this study.\n\nExclusion Criteria:\n\n* Any medical history or evidence of a condition other than AD that may affect cognition.\n* Presence of any significant cerebral abnormalities that would contraindicate lumbar puncture, as assessed on MRI\n* Any other significant cerebral abnormalities that the Investigator considers clinically significant\n* History of schizophrenia, schizoaffective disorder, major depression or bipolar disorder.'\n* Presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological medical conditions which are not stable and adequately controlled or which in the opinion of the investigator could affect the subject's safety in the study or interfere with the study assessments","75 Years",{"count":121,"type":22},50,[91],"This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.",[26],"2026-06-28",{"date":127,"type":38},"2026-06-30",{"date":129,"type":38},"2026-01-27",{"date":131,"type":22},"2030-03-05",{"name":77,"class":78},10,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":59,"phases":144,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100600209","phase-2-a-clinical-trial-to-learn-about-the-effects-of-vhb937-in-people-with-early-alzheimers-disease-100600209","NCT07094516","A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease","A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension","Key Inclusion Criteria\n\n* Male or female participants 50 to 85 years of age\n* Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD\n* Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0\n* Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging\n* Reliable study partner who can accompany the participant at study visits\n* If on symptomatic AD treatment (AChEIs\u002Fmemantine), on a stable dose prior to starting study treatment\n\nKey Exclusion Criteria\n\n* Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia.\n* History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study\n* Transient ischemic attacks (TIA) or stroke occurring within 12 months\n* Clinical evidence of liver or renal disease\u002Finjury\n* Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis\n* Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures\n* Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening\n* Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes\n* Taking any prohibited medications\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","85 Years",{"count":143,"type":22},407,[145],"PHASE2","This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.",[26],[28,149,95,150],"AD","Monoclonal Antibody","2026-06-25",{"date":153,"type":38},"2026-06-26",{"date":155,"type":38},"2025-08-07",{"date":157,"type":22},"2030-12-31",{"name":159,"class":78},"Novartis Pharmaceuticals",74,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":169,"maxAge":141,"enrollmentInfo":170,"targetDuration":4,"studyType":59,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100591114","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-karxt--karx-ec-for-cognitive-impairment-in-alzheimers-disease-100591114","NCT06976216","A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)","MINDSET 1","Inclusion Criteria\n\n* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.\n* Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.\n* Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.\n* Participants on acetyl choline esterase inhibitors (AChEIs) and\u002For memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.\n\nExclusion Criteria\n\n* Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \\\u003C50 mL\u002Fmin), and unstable hypertension or tachycardia.\n* Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.\n* Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.\n* Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","60 Years",{"count":171,"type":22},586,[61],"The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease",[26],[95,176,177,178,179,180],"Cognitive Impairment","Kar-XT","KarX-EC","Mild Alzheimer's Disease","Moderate Alzheimer's Disease",{"date":153,"type":38},{"date":183,"type":38},"2025-07-14",{"date":185,"type":22},"2029-02-23",{"name":187,"class":78},"Bristol-Myers Squibb",116,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":169,"maxAge":141,"enrollmentInfo":197,"targetDuration":4,"studyType":59,"phases":198,"briefSummary":173,"conditions":199,"keywords":200,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":206},"100591113","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-karxt--karx-ec-for-cognitive-impairment-in-alzheimers-disease-mindset-2-100591113","NCT06976203","A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)","MINDSET 2","Inclusion Criteria:\n\n* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.\n* Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.\n* Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.\n* Participants on acetyl choline esterase inhibitors (AChEIs) and\u002For memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.\n\nExclusion Criteria:\n\nParticipants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \\\u003C50 mL\u002Fmin), and unstable hypertension or tachycardia.\n\n* Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.\n* Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.\n* Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":171,"type":22},[61],[26],[95,176,177,178,179,180],{"date":153,"type":38},{"date":203,"type":38},"2025-07-21",{"date":185,"type":22},{"name":187,"class":78},126,{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":59,"phases":217,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":224,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100640516","phase-4-effects-of-ginkgo-biloba-on-blood-biomarkers-in-mild-cognitive-impairment-100640516","NCT07579689","Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment","Effect of Gingko Biloba on the Blood Biomarkers in Mild Cognitive Impairment Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Age 20 years or older\n* Clinical Dementia Rating (CDR) score of 0.5\n* Patients clinically indicated for treatment with Ginkgo biloba extract\n\nExclusion Criteria:\n\n* Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.\n* Refusal to provide informed consent.\n* Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.\n* Known hypersensitivity to Ginkgo biloba extract or any of its components.\n* Pregnant women.\n* Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).\n* Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.","20 Years",{"count":216,"type":22},120,[218],"PHASE4","This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.",[67,26],[67,222,26,223],"Ginexin","Ginkgo Biloba Extract","NOT_YET_RECRUITING","2026-06-24",{"date":153,"type":38},{"date":228,"type":22},"2026-06",{"date":230,"type":22},"2028-12-31",{"name":232,"class":45},"Hanyang University",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":240,"targetDuration":4,"studyType":59,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100641813","phase-1-a-study-to-assess-the-safety-and-effects-of-abbv-1758-following-subcutaneous-or-intravenous-injections-in-participants-with-alzheimers-disease-100641813","NCT07599670","A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease","Inclusion Criteria:\n\n* Participants meeting all the following criteria for Alzheimer's disease (AD):\n\n  * In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.\n  * Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).\n* Participants must have a Mini-Mental State Examination (MMSE) score of 20 or higher at Screening.\n\nExclusion Criteria:\n\n* Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.\n* Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and\u002For any history of abnormal laboratory results that are indicative of significant disease(s).\n* Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.\n* Participants with other significant pathological findings on brain MRI at screening, including but not limited to:\n\n  * Evidence of vasogenic edema\n  * 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)\n  * Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)\n  * Any superficial siderosis\n  * Severe white matter disease",{"count":241,"type":22},210,[91,145],"Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.\n\nABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.\n\nParticipants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.",[26],[26,246],"ABBV-1758","2026-06-18",{"date":249,"type":38},"2026-06-23",{"date":251,"type":38},"2026-05-15",{"date":253,"type":22},"2030-10",{"name":255,"class":78},"AbbVie",11,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":59,"phases":268,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":224,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":283,"locationsCount":111},"100641662","deep-cervical-lymphovenous-anastomosis-for-moderate-alzheimers-disease-100641662","NCT07658430","Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease","The Efficacy and Safety of Deep Cervical LYMphatic-Venous Anastomosis for Moderate Alzheimer's Disease: A Multicenter, Prospective, Randomized Controlled Trial","LYMVA-AD","Inclusion Criteria:\n\n* Aged 50 to 80 years old, male or female.\n* Clinically diagnosed with moderate probable Alzheimer's disease according to the NIA-AA criteria.\n* Baseline Mini-Mental State Examination (MMSE) score between 10 and 20 points.\n* Clinical cognitive decline duration of at least 6 months.\n* Stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement.\n* Able to complete neuropsychological scale assessments, blood biomarker detection and Aβ-PET examination.\n* Have a reliable caregiver who can accompany follow-up visits and assist in completing evaluations.\n* The participant or legal surrogate voluntarily signs the written informed consent.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, renal, respiratory or hematopoietic system dysfunction unable to tolerate surgery or anesthesia.\n* A history of intracranial surgery, severe craniocerebral trauma, stroke, brain tumor or other central nervous system diseases.\n* Other types of dementia, including vascular dementia, frontotemporal dementia, Lewy body dementia, or mixed dementia.\n* Psychiatric disorders requiring long-term medication that may affect cognitive assessment results.\n* Contraindications for PET imaging or contrast agent allergy.\n* Active infection, malignant tumor or severe wasting disease.\n* Pregnancy or breastfeeding status.\n* Participation in other interventional clinical trials within 3 months before enrollment.\n* Poor compliance or inability to complete scheduled follow-up.\n* Any other condition judged inappropriate for enrollment by the investigator.","80 Years",{"count":267,"type":22},296,[269],"NA","This is a multicenter, prospective, open-label, endpoint-blinded randomized controlled clinical study. We aim to evaluate the safety and efficacy of deep cervical lymphovenous anastomosis (LVA) combined with routine treatment for patients with moderate Alzheimer's disease, compared with routine treatment alone.\n\nA total of 296 eligible participants aged 50 to 80 years with moderate Alzheimer's disease will be enrolled and randomly divided into two groups at a 1:1 ratio. One group will receive deep cervical lymphovenous anastomosis plus standard routine treatment, while the other group will only receive standard routine treatment for Alzheimer's disease.\n\nAll participants will be followed up for 12 months after randomization. We will assess cognitive function using MMSE and CDR-SB scales, evaluate caregiver burden via ZBI scale, and detect changes in Alzheimer's disease related biomarkers including blood amyloid-beta and tau protein, as well as Aβ-PET imaging indicators. The main goal is to observe whether this surgical procedure can improve patients' neurological function and clear abnormal protein deposits in the brain, and confirm its long-term safety.\n\nThis study strictly follows ethical principles. Every participant or their legal representative will sign a written informed consent before enrollment. During the whole study period, we will closely monitor all adverse events to ensure the safety of participants.",[26],[26,273,274,275,276],"deep cervical lymphovenous anastomosis","cognitive function","randomized controlled trial","multicenter study","2026-06-13",{"date":279,"type":38},"2026-06-22",{"date":69,"type":22},{"date":282,"type":22},"2029-06-30",{"name":284,"class":45},"Southwest Hospital, China",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":18,"minAge":292,"maxAge":265,"enrollmentInfo":293,"targetDuration":4,"studyType":59,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":307},"100609449","phase-1-a-study-to-evaluate-aln-5288-in-patients-with-alzheimers-disease-100609449","NCT07214727","A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease","A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Is able and willing to meet all study requirements in the opinion of the Investigator\n* Has a diagnosis of Alzheimer's disease (AD) based on clinical findings supported by cerebrospinal fluid (CSF) biomarkers or positive positron emission tomography (PET) amyloid imaging within 7 years prior to screening\n* Has mild cognitive impairment (MCI) or dementia due to AD\n\nExclusion Criteria:\n\n* Has non-AD dementia\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2× upper limit of normal (ULN)\n* Has total bilirubin \\>1.5×ULN\n* Has known human immunodeficiency virus infection\n* Has history of hepatitis C virus or current hepatitis B virus infection\n* Has systolic blood pressure \\>160 mmHg and\u002For a diastolic blood pressure \\>100 mmHg after 10 minutes of rest at screening\n* Has an estimated glomerular filtration (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73 m\\^2 at screening\n* Has clinically significant ECG abnormalities at screening\n* Has uncontrolled psychiatric disease, including patients deemed by the Investigator to be at significant risk of suicide, major depressive episode, psychosis, confusional state, or violent behavior\n* Has history of bleeding diathesis or coagulopathy due to chronic conditions\n* Has a medical history of brain or spinal disease that would interfere with the IT injection and LP procedures\n* Has history of uncontrolled seizures within the last 6 months prior to Screening","40 Years",{"count":121,"type":22},[91],"The purpose of this study is to:\n\n* Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)\n* Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration",[26],[149,95],"2026-06-10",{"date":300,"type":38},"2026-06-12",{"date":302,"type":38},"2025-10-15",{"date":304,"type":22},"2030-03-06",{"name":306,"class":78},"Alnylam Pharmaceuticals",13,{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":52,"acronym":313,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":314,"targetDuration":4,"studyType":59,"phases":315,"briefSummary":62,"conditions":316,"keywords":317,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":324,"locationsCount":325},"100606023","phase-3-a-clinical-trial-of-trontinemab-in-participants-with-early-symptomatic-alzheimers-disease-100606023","NCT07170150","A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease","TRONTIER 2",{"count":58,"type":22},[61],[64],[66,67,68],"2026-06-05",{"date":320,"type":38},"2026-06-09",{"date":322,"type":38},"2025-11-12",{"date":75,"type":22},{"name":77,"class":78},150,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":334,"targetDuration":4,"studyType":59,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":348},"100606576","phase-3-screening-study-to-determine-individuals-with-potential-trial-eligibility-for-alzheimers-disease-studies-100606576","NCT07177352","Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies","Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition","TRAVELLER","Inclusion Criteria:\n\n\\- Report of objective or subjective memory concerns (by the participant and\u002For their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.\n\nExclusion Criteria:\n\n* Dependency in basic activities of daily living (bADLs) due to cognitive impairment\n* Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)\n* Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD\n* History of severe, clinically significant central nervous system trauma\n* Any serious medical condition that precludes a participant's safe participation and completion of a clinical study",{"count":335,"type":22},13000,[61],"This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.",[64],[66,67,68],"2026-06-03",{"date":342,"type":38},"2026-06-04",{"date":344,"type":38},"2025-07-02",{"date":346,"type":22},"2035-07-31",{"name":77,"class":78},211,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":141,"enrollmentInfo":357,"targetDuration":4,"studyType":59,"phases":359,"briefSummary":360,"conditions":361,"keywords":366,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":46},"100474761","phase-1-a-study-to-assess-the-effects-of-aci-24060-in-alzheimers-disease-and-in-down-syndrome-abate-study-100474761","NCT05462106","A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)","A Phase 1b\u002F2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)","Inclusion Criteria:\n\nStudy Part 1a and Part 1b\n\n1. Age ≥50 and ≤85 years at screening.\n2. Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging Alzheimer's Association (NIA-AA) criteria.\n3. PET scan at screening consistent with the presence of amyloid pathology.\n4. Clinical Dementia Rating (CDR)-Global Score of 0.5.\n5. Subjects either not taking any marketed treatment for AD or receiving a stable dose of an acetylcholinesterase inhibitor (ACHEI) and\u002For memantine for at least 2 months prior to screening.\n\nStudy Part 2\n\n1. Age ≥35 and ≤50 years at screening (subjects with DS with age ≥35 and ≤39 years may be considered on the condition that there is prior evidence of amyloid results compatible with AD pathology at PET-scan and\u002For in biofluids).\n2. Male or female subjects with DS with a cytogenetic diagnosis being either trisomy 21 or complete unbalanced translocation of chromosome 21.\n3. PET scan at screening consistent with the presence of amyloid pathology.\n4. Mild to moderate intellectual disability as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification.\n5. Subjects must have a study partner who has direct and regular contact, at least 10 hours per week, with the subject and who is able to provide reliable answers to questions related to the subject, according to the study investigator.\n\nExclusion Criteria:\n\n1. Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of the study treatment (eg, moderate and\u002For severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.\n2. DSM-5 criteria for substance use disorders drug or alcohol abuse or dependence (with the exception of tobacco use disorder) currently met within the past 5 years.\n3. History or presence of uncontrolled seizures. If there is a history of seizures, they must be well controlled, with no occurrence of seizures in the 2 years before study screening. The use of antiepileptic medications is permitted.\n4. Concomitant or history of clinically significant and\u002For unstable psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and\u002For non-hemorrhagic stroke). Subjects with a history of major depressive disorder may be included if they have been free of major episodes for at least 1 year before screening.\n5. History of meningitis or meningoencephalitis.\n6. History of moderate or severe traumatic brain injury.\n7. History or presence of inflammatory neurological disorders.\n8. History or presence of immunological or autoimmune disorders.\n9. History of severe allergic reaction (eg, anaphylaxis) including, but not limited to severe allergic reaction to previous vaccines, foods, and\u002For medications.\n10. Significant risk of suicide, defined using the C-SSRS as the subject answering \"yes\" to suicidal ideation questions 4 or 5 or answering \"yes\" to suicidal behavior within the past 12 months.\n11. MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or evidence of a previous macro-hemorrhage or showing more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as \"possible\" or \"definite\"). Evidence of space occupying lesions other than benign meningioma of less than 1 cm diameter, more than 2 lacunar infarcts, or 1 single infarct larger than 1 cm in diameter. Screening MRI scan showing structural evidence of alternative pathology not consistent with AD and is considered to be at the origin of subject's symptoms.\n12. Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.\n13. Subjects with a positive Human Immunodeficiency Virus (HIV-1 and 2) test at screening.\n14. Subjects with clinical or laboratory evidence of active hepatitis B or C at screening (eg, HBV or HCV antigens).\n15. Subjects with positive syphilis serology consistent with active syphilis at screening.\n16. Subjects with presence of antibody titers related to immunological or autoimmune disorders at screening.\n17. MRI examination cannot be done for any reason, including but not limited to metal implants contraindicated for MRI and\u002For severe claustrophobia.\n18. Any contraindication for PET scan imaging.\n19. Any contraindication to lumbar puncture in subjects undergoing this procedure (note: lumbar puncture is optional in subjects with DS).\n20. Previous treatment with ACI-24 or any other active immunotherapy against AD at any time in the past unless there is firm evidence that the subject received placebo only and the placebo formulation is not expected to induce any specific immune response.\n21. Previous treatment with any investigational and\u002For marketed passive immunotherapy against AD within 6 months before screening or 5 half-lives, whichever is longer, unless there is firm evidence that the subject received placebo only.\n22. Ongoing treatment with any approved anti-amyloid passive immunotherapy for Alzheimer's disease.\n23. Use of acetylcholinesterase inhibitor or glutamatergic drugs (eg, memantine, topiramate, lamotrigine) if not on stable dose for at least 2 months before screening.\n24. Any vaccine, either live or not, including but not limited to influenza or COVID-19 vaccine, received within 4 weeks before randomization.\n25. Subjects with treated hypothyroidism not on a stable dose of replacement medication for at least 2 months before screening and having clinically significant abnormal serum T4 and\u002For thyroid stimulating hormone at screening.\n26. Subjects undergoing lumbar puncture and being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower.\n27. Use of antidepressants (other than selective serotonin reuptake inhibitors\u002Fserotonin-norepinephrine reuptake inhibitors at stable dose); typical antipsychotics; γ-aminobutyric acid agonists (eg, gabapentin); or stimulants (eg, methylphenidate, modafinil). Stable doses of atypical antipsychotics or benzodiazepines are only allowed if this is not considered to influence the safety and the efficacy of the study treatment according to the site investigator and the sponsor medical monitor.\n28. Chronic use of opioid analgesics. A limited treatment duration for acute conditions until 24 hours before cognitive assessment is allowed.\n29. Current use of immunosuppressant or immunomodulating drugs or their use within the 6 months before study screening. Current use of oral steroids or their use within the 3 months before study screening.\n\n    Additional Exclusion Criteria in Study Part 2\n\n    The following are exclusion criteria at the time of randomization but will not be considered as exclusionary after treatment assignment:\n30. Clinical diagnosis of AD dementia in DS as per International Classification of Diseases 10 (ICD-10).\n31. DSQIID \\>20.\n32. Intelligence quotient score \\\u003C40 (KBIT-2).","35 Years",{"count":358,"type":22},304,[91,145],"The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.",[362,363,364,365,26],"Amyloid Plaque","Beta-Amyloid","DSAD","Prodromal Alzheimer's Disease",[95,367,368,362,363,369,370,371,372,373,364,28],"Brain Diseases","Central Nervous System Diseases","Down syndrome","Immunogenicity","active immunotherapy","immune response","anti-amyloid therapy","2026-05-27",{"date":376,"type":38},"2026-05-29",{"date":378,"type":38},"2022-06-21",{"date":380,"type":22},"2029-04",{"name":382,"class":78},"AC Immune SA",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":17,"sex":18,"minAge":169,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":59,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":111},"100558213","phase-1-tread-time-restricted-eating-intervention-for-alzheimers-disease-100558213","NCT06548191","TREAD: Time Restricted Eating Intervention for Alzheimer's Disease","TREAD","Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nInclusion criteria\n\n1. Persons, aged ≥60 years\n2. In good general health as evidenced by medical history or diagnosed with clinical diagnosis of MCI\u002FAD: meeting research consensus criteria for probable MCI or dementia due to AD, requiring positive amyloid biomarkers in brain or cerebrospinal fluid (CSF) obtained at their regular point of care or study referral no longer than 3 months prior to screening.\n3. Ability and willingness to complete cognitive evaluations, blood draw, actigraphy monitoring and to record fasting times daily.\n4. Daily night fasting \\\u003C12h at baseline. Ability and willingness to follow an eating protocol of prolonged night fasting for 14 h\n5. For cognitively normal living partners in the dyads group, scores \\>26 in the Montreal Cognitive Assessment (MoCA) test administered at screening.\n\nExclusion Criteria:\n\n1. Clinical diagnosis with a neurodegenerative condition other than MCI\u002FAD.\n2. Presenting cognitive impairment not due to AD.\n3. Clinical diagnoses of diabetes.\n4. Actively using insulin in the past 6 months.\n5. Started a new medication (or changed doses) indicated for the treatment of MCI\u002FAD in the last three months prior to enrollment.\n6. Currently taking any medication known to affect appetite, inlcuding but not limited to GLP-1 agonists.\n7. Any history of disordered eating, including difficulty swallowing and refusal to eat.\n8. Currently engaged in shift work.\n9. In treatment with another investigational drug.\n10. Body Mass Index (BMI) \\\u003C20. or \\>35",{"count":391,"type":22},60,[91],"The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults. The main questions it aims to answer are:\n\n* Does prolonged nightly fasting of 14 h can reduce markers of AD pathology and aging and reduce cognitive and sleep alterations in MCI and AD patients?\n* Can patients with MCI and early \u002Fmoderate AD sustain time-restricted eating for 3 to 6 months? Researchers will compare participants who fast for 14 h per night during 3 months to those who fast for less than 12 h\u002Fnight. Researchers will also compare participants that fast for 3 months to those who fast during 6 months, to determine the effective duration of the intervention. Finally, researchers will evaluate whether following the time-restricted eating diet alongside a partner actively following the same diet, will increase adherence to the protocol compared to subjects that fast alone.\n\nParticipants will:\n\n* Fast for 14 h a night (stop eating at 8 pm and start eating the following morning at 10 am) for 3 or 6 months\n* Visit the clinic three times (at the beginning of the study, 6 and 12 months later)\n* Provide blood samples and take a cognitive test during clinic visits\n* Keep a diary (or use an app on a smart phone) to record time of eating\n* Wear an activity tracker watch",[67,395,26],"Alzheimer Disease",[397,398,399,67,395,400,401,402],"Time-Restricted Eating","Intermittent Fasting","Prolonged Nightly Fasting","Circadian Rhythms","Cognition","Neuropathology","2026-05-21",{"date":405,"type":38},"2026-05-26",{"date":407,"type":38},"2025-04-23",{"date":409,"type":22},"2027-06-30",{"name":411,"class":45},"University of California, San Diego",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":59,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":111},"100635488","phase-2-safety-assessment-of-leronlimab-and-its-effect-on-brain-inflammation-in-alzheimers-disease-100635488","NCT07553338","Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease","Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease","SALIENT-AD","Inclusion Criteria:\n\nPotential participants are required to meet all the following criteria for enrollment into the study:\n\n1. Adult males or females, 50 years of age and older\n2. Biomarker confirmed mild-to-moderate i.e., mild cognitive impairment\u002FAD (MCI\u002FAD) based on standard criteria (CDR 0.5 to 1.5).\n3. Cognition intact enough to participate in study procedures including cognitive testing (MoCA\\>11)\n4. Clinically normal resting 12-lead ECG at screening or, if abnormal, considered not clinically significant by the investigator\n5. Participant (or legally authorized representative) provides written informed consent prior to initiation of any study procedures\n6. Understands and agrees to comply with planned study procedures\n7. If receiving an FDA approved drug that treat the symptoms of AD (e.g., cholinesterase inhibitors and\u002For memantine) must be on a stable dose for at least 12 weeks prior to baseline\n8. If receiving an FDA approved drug that targets brain amyloid must be on a stable dose for at least 12 weeks prior to baseline\n9. If the participant is taking any supplement or medical food that may affect brain function must be on a stable dose or regimen for at least 12 weeks prior to baseline\n10. Participants on permitted concomitant medications should be on a stable dose of the permitted concomitant medication for at least 4 weeks unless a shorter duration is deemed acceptable by the investigator\n11. In the opinion of the investigator, have adequate cognition, literacy, vision, and hearing for neuropsychological testing\n12. The participant should have a study partner who can support the study participant and provide collateral information.\n\nExclusion Criteria:\n\nPotential participants meeting any of the following criteria will be excluded from enrolment into the study:\n\n1. Participant with a gene variation that would inhibit binding to the PET radiotracer (11C-DPA-713) and\u002For clinical factors that could affect PET signal, such as chronic use of benzodiazepines or NSAIDS\n2. Women who are pregnant or breastfeeding at screening or baseline\n3. Females of childbearing potential who within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following: (1) total abstinence, if it is their preferred and usual lifestyle; (2) an intrauterine device or intrauterine hormone-releasing system; (3) a contraceptive implant; (4) an oral contraceptive (with additional barrier method) with the participant being on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation; (5) have a vasectomized partner with confirmed azoospermia. Women who do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation shall be excluded. However, at the discretion of the investigator it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, i.e., double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical\u002Fvault cap with spermicide. NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).\n4. Male participants with female partners of childbearing potential are not eligible to participate if they do not agree to ONE of the following from the time prior to first dosing until 90 days after the last dose of study treatment: (1) are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; (2) Agree to use a male condom plus partner use of a contraceptive method with a failure rate of \\\u003C1% per year when having penile-vaginal intercourse with a partner of childbearing potential who is not currently pregnant. Men with a pregnant or breastfeeding partner are not eligible to participate if they do not agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration from the time prior to first dosing until 90 days after the last dose of study treatment\n5. Participants who are HIV positive at screening\n6. Participants with a past history (suspected or confirmed) of Hepatitis B should have HBsAg testing at screening and are excluded if HBsAg is positive\n7. Participants with a past history (suspected or confirmed) of Hepatitis C should have HCV RNA PCR testing at screening and are excluded if the HCV RNA PCR test is positive\n8. Presence based on exam, history or MRI of significant brain disease other than AD such as schizophrenia, epilepsy, Parkinson's disease or large territory stroke\n9. Current substance abuse in accord with Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria\n10. Significantly depressed (Geriatric Depression Scale \\> 10)\n11. Contraindications to MRI scanning, including claustrophobia, cardiac pacemaker\u002Fdefibrillator, ferromagnetic metal implants (e.g., in skull and cardiac devices other than those approved as safe for use in MRI scanners)\n12. Contraindications to PET\n13. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at screening or baseline which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety\n14. Any other medical conditions (e.g., cardiac, respiratory, gastrointestinal, or renal) which are not stable and\u002For adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments\n15. Participants with malignant neoplasms within 3 years of screening (except for basal or squamous cell carcinoma in situ of the skin or localized prostate cancer in male participants). Participants who had malignant neoplasms but who have had at least 3 years of documented uninterrupted remission before screening need not be excluded\n16. Participants who are participating in other interventional clinical trials that in the opinion of the investigator is likely to interfere with participation in or completion of the study or to affect study results or interpretation.\n17. Participants who were dosed in a clinical trial involving any new investigational drug for AD within 12 months prior to screening unless it can be documented that they received placebo\n18. Participants are not eligible if they have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab\n19. Participants who have previously received leronlimab\n20. Participants who are taking prohibited medications\n21. Inability for patient or proxy to provide informed consent or to comply with test requirements\n22. Visual or hearing impairment that, in the opinion of the investigator, would prevent the participant from performing psychometric tests accurately",{"count":421,"type":22},20,[145],"The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of cancer, its safety and tolerability in AD will be tested for the first time. The main purpose of this study is to learn:\n\n1. Is this drug safe for participants with AD and MCI due to AD?\n2. Does leronlimab change levels of brain inflammation?\n\nThe results of this study could lead to future studies with more participants that will test whether leronlimab may slow or prevent the decline in thinking abilities and brain function in this group of participants. Using leronlimab for Alzheimer's disease is experimental, which means that the Food and Drug Administration (FDA) has not approved leronlimab for this purpose.\n\nParticipants will be asked to take leronlimab once a week for 12 weeks in our clinic or in their own home. Participants will also be asked to complete the below procedures before and after taking leronlimab for 12 weeks:\n\n1. Undergo 2 types of brain scans, Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI).\n2. Visit our clinic for routine lab work, an electrocardiogram (ECG), and a physical exam.\n3. Donate blood so the researchers can better understand how leronlimab affects levels of inflammation and proteins related to AD in the blood.\n4. Undergo a series of tests and questionnaires that test thinking abilities.\n5. Have weekly phone calls with researchers to let them know if there are side effects while taking this drug.",[425,26],"Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease",[26,67,427],"Clinical Trial","2026-05-19",{"date":430,"type":38},"2026-05-22",{"date":432,"type":38},"2026-04-30",{"date":434,"type":22},"2027-11",{"name":436,"class":45},"Weill Medical College of Cornell University",{"id":438,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":440,"keywords":441,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":46},"100123128",{"count":21,"type":22},[26],[28,29,30,31,32,33],"2026-05-12",{"date":251,"type":38},{"date":40,"type":4},{"date":446,"type":22},"2026-07",{"name":44,"class":45},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":265,"enrollmentInfo":455,"targetDuration":4,"studyType":59,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":472},"100598559","deep-cervical-lymphatic-venous-anastomosis-in-the-treatment-of-alzheimers-disease-clean-ad-100598559","NCT07073066","Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)","Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease: A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial (CLEAN-AD)","Inclusion Criteria:\n\n1. Age 50-80 years, male or female.\n2. Diagnosed with AD according to NIA-AA criteria.\n3. Moderate-to-severe AD dementia, defined as Clinical Dementia Rating Scale Global Score (CDR-GS) ≥1.\n4. Mini-Mental State Examination (MMSE) score 10-20.\n5. The course of AD more than 6 months.\n6. If receiving an approved AD treatment, must be on a stable drug dose for at least 3 months prior to Baseline. AD Treatment-naïve subjects can be entered into the study.\n7. Have an identified caregiver (defined as a person able to support the subject for the duration of the study and who spends at least 8 hours per week with the subject). The caregiver must accompany with the participant at all study follow-up visits.\n8. Signed informed consent (from the participant or their relative, and the caregiver).\n\nExclusion Criteria:\n\n1. Any neurological condition other than AD that may affect cognitive function, including stroke, Parkinson's disease, epilepsy, intracranial tumors or space-occupying lesions, traumatic brain injury, intracranial infections, metabolic encephalopathy, etc.\n2. Other causes of dementia, including vascular dementia, hereditary cerebral small vessel disease, vitamin deficiency, or any other etiology leading to dementia.\n3. Previous evidence of severe stenosis (≥70%) in the middle cerebral artery and\u002For internal carotid artery.\n4. Presence of primary psychiatric disorders (such as schizophrenia, schizoaffective disorder, major depressive disorder, or bipolar disorder) rather than psychiatric symptoms caused by AD.\n5. Severe neurological deficits in limb movement, language, vision, hearing, or consciousness, or any condition that the investigator determines may prevent the completion of cognitive function assessments.\n6. History of drug or alcohol abuse or dependence.\n7. History of malignant tumors or prior radiotherapy or surgery involving the head and neck.\n8. Major surgical procedures or severe head or body trauma within the past 30 days.\n9. Presence of other life-threatening conditions with an expected survival time of less than 2 years.\n10. Contraindications to head MRI (including cardiac pacemakers\u002Fdefibrillators, ferromagnetic metal implants, etc.).\n11. Severe diseases or functional impairment of the heart, lungs, liver, kidneys, or other solid organs, making the patient unable to tolerate anesthesia or DC-LVA.\n12. Severe bleeding tendency (including but not limited to): platelet count \\\u003C100×10⁹\u002FL; heparin therapy within the last 48 hours with APTT ≥35 seconds; ongoing warfarin use with INR \\>1.7.\n13. Requirement for long-term use of antithrombotic medications, with inability to discontinue them before surgery or potential risks associated with discontinuation.\n14. Uncontrolled persistent hypertension (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>95 mmHg).\n15. Co-infection with HIV or Treponema pallidum, or any uncontrolled infectious disease.\n16. Use of other investigational drugs or devices within 30 days prior to obtaining informed consent, or current participation in other interventional clinical studies.\n17. Pregnancy, lactation, potential for pregnancy, or plans for pregnancy during the study period.\n18. Immediate family members of the investigator (spouse, parents, children, or siblings), staff of the research institution or third-party organizations, or any other individuals with potential conflicts of interest related to the study.",{"count":456,"type":22},376,[269],"This multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial is to evaluate the efficacy and safety of deep cervical lymphatic venous anastomosis (DC-LVA) plus usual care versus usual care in reduing the score of clinical dementia rating-sum of boxes (CDR-SB) at 12 months in patients with moderate-to-severe Alzheimer's Disease (AD).",[64],[461,462,463],"Alzheimers disease","Cervical Lymphatic Venous Anastomosis","Randomized Controlled Trial","2026-05-08",{"date":442,"type":38},{"date":467,"type":38},"2026-03-13",{"date":469,"type":22},"2029-11-30",{"name":471,"class":45},"Beijing Tiantan Hospital",9,{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":224,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":111},"100637004","validation-study-of-the-exsem-battery-designed-to-differentiate-the-contribution-of-executive-functions-in-semantic-disorders-100637004","NCT07573046","Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders","ExéSemVal","Inclusion Criteria:\n\n* \\- Participants without cognitive impairment\n* Participant aged 50 to 90 years (inclusive);\n* Participant whose native language is French\n* Participant affiliated with or entitled to a social security scheme;\n* Participants who have been informed and have not objected.\n* Participants with cognitive impairment\n* Participant aged 50 to 90 years (inclusive);\n* Participant whose native language is French\n* Participant receiving memory care with a diagnosis of Alzheimer's disease, at the stage of minor or major neurocognitive impairment, according to the 2011 NIA-AA criteria (McKahn et al., 2011), or with a diagnosis of vascular neurocognitive impairment according to the VasCog-2-WSO diagnostic criteria (Sachdev et al., 2025), or with a diagnosis of primary progressive aphasia with semantic variant (Gorno-Tempini et al., 2011).\n* Mini-Mental State Examination (MMSE) score ≥ 20\u002F30, within the 6 months preceding enrollment;\n* Participants affiliated with or entitled to a social security scheme;\n* Participants who have been informed and have not objected.\n\nExclusion Criteria:\n\n* \\- For all participants:\n* Severe, progressive, or unstable medical conditions that may interfere with assessment variables (epilepsy, acute psychiatric or psychotic disorders, visual hallucinations, acute infection);\n* Substance use that may affect cognitive performance;\n* Deafness or blindness that may compromise the participant's assessment or participation in tasks and scales;\n* Participants under guardianship, curatorship, or legal protection;\n* Pregnant, postpartum, or breastfeeding women.\n* Specifically for participants without cognitive impairment:\n* Participants previously diagnosed with cognitive impairment.\n* Specifically for participants with cognitive impairment:\n* Severe behavioral and psychological symptoms that prevent task completion, as determined by the investigator.",{"count":481,"type":22},140,"This protocol describes a study aimed at evaluating the psychometric properties of the ExéSem battery, developed to differentiate semantic deficits from executive semantic impairments in patients with post-lesional or neurodegenerative anomia. Currently available tools do not allow a straightforward distinction between these deficits, limiting diagnostic accuracy and clinical management. The ExéSem battery was developed through a collaboration between Hospices Civils de Lyon, the University of Mons, and Laval University to address this gap.\n\nThe battery includes three main tasks: (1) a dual task combining semantic judgment and semantic matching using identical items, (2) a word-picture matching task, and (3) a rapid naming task. Each task is designed to manipulate the level of executive control required to access semantic representations. This allows the identification of whether performance declines under increased executive demand, thereby distinguishing executive-related semantic impairments.",[26,484,485,486],"Vascular Neurocognitive Disorder","Progressive Primary Aphasia Semantic Variant","People Without Neurocognitive Disorder",[488,489,490,491],"Anomia","Semantic disorders","Executive control","Neurocognitive disorders","2026-05-04",{"date":494,"type":38},"2026-05-07",{"date":496,"type":22},"2026-09-09",{"date":498,"type":22},"2029-09-09",{"name":500,"class":45},"Hospices Civils de Lyon",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":292,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":59,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":111},"100459250","study-on-the-effect-of-40-hz-non-invasive-light-therapy-system-100459250","NCT05260177","Study on the Effect of 40 Hz Non-Invasive Light Therapy System","ALZLIGHT Stage III - Study on the Effect of 40 Hz Non-Invasive Light Therapy System","Inclusion Criteria:\n\n* Adult competent person, able to understand the nature of the study and give written informed consent.\n* Diagnosed with probable mild to moderate AD based on NIA-AA diagnostic criteria or in a prodromal stage of AD with at least one positive biomarker of AD.\n* Age \\> 40 years. Females must be post-menopausal.\n* Fluent in Danish.\n* \\> 8 years of normal school education\n* Pass a color-blindness test (Ishihara color test)\n* Have visual and auditory capabilities, and language skills necessary for neuropsychological testing.\n* Participants must have a designated caregiver, who is available to the participant and can provide the necessary assistance with using the LTS device and the Actigraph wearable at home and assist with clinical visits and other practical issues\n\nExclusion Criteria:\n\n* Profound visual impairment (visual acuity \\> 0.5) provided correction with spectacles, if needed\n* Significant abnormalities related to important parts of the brain, e.g., the visual system, prefrontal cortex, or hippocampus, or relevant lesions detected by pre-trial imaging.\n* Prior history of significant diseases related to the visual system or the brain.\n* Medication: Use of any antiepileptic drugs, neuromodulating drugs or high dose of sedatives will be excluded.\n* Prior history of substance abuse within the past 2 years.\n* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the PI)",{"count":509,"type":22},62,[269],"The ALZLIGHT STAGE III Study is a continuation of the ALZLIGHT Pilot - Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System. As with the first two stages, this study will examine whether entrainment of 40 Hz neural oscillation by novel 40 Hz Invisible Spectral Flicker is a potential therapy for Alzheimer's Disease. In order to examine this, 62 patients with mild to moderate Alzheimer's Disease will be recruited. The patients will be exposed to the Non-Invasive Light Therapy System for 1 hour a day for 6 months. The effect will be measured by a combination of electroencephalography, cognitive testing, functional magnetic resonance imaging, magnetic resonance spectroscopy and actigraphy.",[26],[514,515,516,517,518,519,520,521],"Gamma Entrainment","40 Hz","Invisible Spectral Flicker","LED","Light Therapy","Brain Stimulation","Gamma Oscillations","Gamma Induction",{"date":494,"type":38},{"date":524,"type":38},"2022-09-20",{"date":526,"type":22},"2028-12-01",{"name":528,"class":45},"Zealand University Hospital",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":17,"sex":18,"minAge":292,"maxAge":141,"enrollmentInfo":537,"targetDuration":4,"studyType":59,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":111},"100542094","social--affective-cognition-in-alzheimers-disease--associated-disorders-100542094","NCT06338397","Social & Affective Cognition in Alzheimer's Disease & Associated Disorders","Social & Affective Cognition as Determinant of Social Behavior in Alzheimer's Disease & Associated Disorders","SOCIALIZE","Inclusion Criteria:\n\n* Men and women;\n* 40 to 85 years of age (included);\n* Registered with the French Social Security;\n* Have a study partner. The study partner is required to complete several scales. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor.\n* Fluent in French, able to read and write;\n\nExclusion Criteria:\n\n* Participants who have contraindications to perform an MRI scan;\n* Participants with significant sensory deficits that are not corrected by suitable devices.\n* Participants with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load, in the judgment of the investigator;\n* Participants with other neurodegenerative disease such as Lewy body dementia and Parkinson's disease;\n* Participants with other serious neurological disorder such as brain tumor, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;\n* Participants with excessive alcohol intake or drug abuse, in the judgment of the investigator;\n* Participants who, in the opinion of the investigator, have a risk of non-compliance to the study procedures;",{"count":216,"type":22},[269],"Recent studies have shown that individual neuropsychological scores of patients with Alzheimer's disease and Associated Disorders (ADAD) are only poorly correlated to their behavioral difficulties, such as disinhibition, apathy, social decision-making or vulnerability. Recently, social \\& affective cognitive disorders have been highlighted as potential cause of social behavioral abnormalities. However, no previous studies have assessed the specific relationship between social \\& affective cognition \\& social behavior in ADAD. Our pilot study aims to explore the correlations between core and extended social \\& affective cognitive processes and social behavior as observed during the neuropsychological examination, as well as to explore the common brain regions involved in those domains.",[26,541],"Frontotemporal Degeneration (Semantic & Behavioral Variants)",[543,544,545,546,547],"Emotions","social cognition","social semantics","neuropsychology","frontotemporal dementia","2026-04-29",{"date":432,"type":38},{"date":551,"type":38},"2025-01-28",{"date":553,"type":22},"2028-05-02",{"name":555,"class":45},"University Hospital, Lille",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":169,"maxAge":141,"enrollmentInfo":564,"targetDuration":4,"studyType":59,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":256},"100522861","study-to-evaluate-the-efficacy-and-safety-of-atnc-mdd-v1tms-with-cognitive-training-in-mild-alzheimers-dementia-100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.",{"count":565,"type":22},180,[269],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[26,95,367,368,569,570,571,572],"Nervous System Diseases","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorder",[574,575,576,95],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":579,"type":38},"2026-04-23",{"date":581,"type":38},"2023-05-15",{"date":409,"type":22},{"name":584,"class":78},"Advanced Technology & Communications",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":119,"enrollmentInfo":592,"targetDuration":4,"studyType":59,"phases":594,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":224,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":111},"100623633","phase-2-study-to-evaluate-the-effect-of-ht-4253-for-the-prevention-of-alzheimers-disease-in-apoe4-carriers-100623633","NCT07399171","Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","Inclusion Criteria:\n\n1. Participant must be 50-75 years of age, without previous AD diagnosis at the time of signing the informed consent.\n2. Capable of giving signed informed consent.\n3. Body mass index (BMI) between 18 and 32 kg\u002Fm2.\n4. A positive amyloid probability score from PrecivityAD2™ test (≥ 47.5).\n5. APOE4 carrier: homozygous (APOE4\u002FAPOE4) or heterozygous (APOE3\u002FAPOE4), confirmed using the Precivity-ApoE™ test.\n6. Must be ambulatory.\n7. Must be in good health, as determined by the PI, without clinically significant medical history.\n8. Normal physical examination, 12-lead ECG, and vital signs, as determined by the PI.\n9. Females must meet one of the following:\n\n   * Postmenopausal\n   * Surgically sterile\n10. Male participants who are sexually active with a woman of childbearing potential must agree to use a double contraception during the study and for 30 days after the last dose of HT-4253.\n11. Female participants must have a negative serum pregnancy test (β-human chorionic gonadotropin \\[β-hCG\\]) at screening.\n12. Able to comply with the study procedures in the view of the PI.\n\nExclusion Criteria:\n\n1. Any medical or neurological condition that in the opinion of the PI may be supportive of dementia.\n2. A history of subjective memory decline with gradual onset and slow progression over the 6 months prior to Screening.\n3. Previous or current diagnosis of AD or mild cognitive decline: MoCA \\\u003C 26.\n4. Any clinically significant CNS, cardiac, pulmonary, renal, gastrointestinal, endocrinological, respiratory, or metabolic conditions (or history), or other pathological or physiological conditions, that might interfere with the study results in the PI's opinion.\n5. Any condition which, in the PI's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study.\n6. History of clinically significant unstable psychiatric illness at the PI's discretion (e.g., uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder) Note: Well-controlled and stable major depressive disorder or anxiety is permitted.\n7. Prior treatment with an investigational LRRK2 inhibitor or any investigational AD therapy within the 6 months prior to Screening.\n8. Concomitant use of prescription medications primarily indicated for psychiatric disorders or neurodegenerative disease (e.g., antipsychotics, mood stabilizers, investigational agents) within 30 days prior to first dose of study drug (Study Day 1).\n9. Transient ischemic attack or stroke or any unexplained loss of consciousness (e.g., fainting without a diagnosis) within 1 year prior to Screening.\n10. Known cerebral or systemic vasculopathy.\n11. History of seizure or convulsion within 3 years prior to Screening or progressive neurologic disease (Parkinson's with dementia, epilepsy with breakthrough seizures, normal pressure hydrocephalus, multiple sclerosis with recent relapse).\n12. Have donated blood or had loss of blood of more than a single unit of blood within 8 weeks before Screening or intend to donate blood during the course of the study.\n13. Poorly controlled diabetes mellitus, as defined by having dosage adjustment of diabetic medication within 3 months prior to first dose of study drug (Study Day 1).\n14. History of unstable angina, myocardial infarction, and\u002For chronic heart failure.\n15. Chronic, uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 95 mmHg).\n16. Vaccinations within 10 days prior to Screening.\n17. Use of any medications, including prescription, over the counter (OTC) medications, vitamins, herbal preparations, and supplements, that, in the opinion of the PI, may put the participant at higher risk for AEs, or impair the participant's ability to complete study procedures.\n18. Use of other investigational drugs at the time of Screening or within 30 days or 5 half-lives prior to signing of the ICF, whichever is longer, or longer if required by local regulations.\n19. History of heavy smoking (i.e., more than 10 cigarettes a day or the tobacco\u002Fnicotine equivalent) within 3 months of Screening or refuse to abstain from tobacco or nicotine-containing products throughout the duration of the study.\n20. History of, or current substance use disorder, including heavy alcohol use.\n21. Pregnant or breastfeeding.\n22. Presence of any laboratory abnormalities at Screening.\n23. Prolonged QT interval exclusions for QTcF \\>450 ms for males and \\>470 ms for females Note: Entry of any participant with an abnormal ECG must be approved and documented by signature of the PI or a medically qualified sub-investigator.\n24. Impaired renal function with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2.",{"count":593,"type":22},112,[145],"Primary Objectives:\n\nTo demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score.\n\nSecondary Objectives:\n\n* To assess the effects of HT-4253 on tau related blood biomarker progression over the study period.\n* To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period.\n* To assess the safety and tolerability of HT-4253 in the UAE population.",[64],"2026-04-16",{"date":599,"type":38},"2026-04-17",{"date":601,"type":22},"2026-04-03",{"date":603,"type":22},"2027-08-20",{"name":605,"class":78},"Halia Therapeutics, Inc.",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":613,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":111},"100578412","a-postmarketing-study-of-leqembi-in-south-korean-participants-with-alzheimers-disease-100578412","NCT06810960","A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease","A 6-Year Postmarketing Safety and Clinical Outcome Study of LEQEMBI® in the Treatment of Alzheimer's Disease Using Real-World Data From South Korean Patients Enrolled Into the South Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) Registry","Inclusion Criteria:\n\n* Enrolled in JOY-ALZ before the decision to treat with LEQEMBI\n* The clinical decision to treat with LEQEMBI has already been made\n* Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinical study","19 Years",{"count":615,"type":22},3000,"The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.",[26],[26,619,620],"LEQEMBI","ARIA",{"date":577,"type":38},{"date":623,"type":38},"2025-02-24",{"date":625,"type":22},"2029-09-30",{"name":627,"class":78},"Eisai Korea Inc.",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":17,"sex":18,"minAge":169,"maxAge":56,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":637,"conditions":638,"keywords":643,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":46},"100560992","development-of-a-database-to-investigate-digital-and-blood-based-biomarkers-and-their-relationship-to-tau-and-amyloid-pet-imaging-in-older-participants-who-are-cognitively-normal-cn-have-mild-cognitive-impairment-mci-or-have-mild-to-moderate-ad-dementia-100560992","NCT06584357","Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia","Bio-Hermes-002","Inclusion Criteria:\n\nPre-screening Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to progress to Visit 1 (Screening):\n\n1. Participant is between 60 to 90 years of age (inclusive) at the time of consent; and\n2. Participant has a study partner who has sufficient and frequent contact with the participant (defined as at least 8 hours of contact a week) and is able to provide accurate information regarding the participant's cognitive and functional abilities.\n\nCore Study Inclusion Criteria\n\nParticipants must meet ALL of the following criteria, in addition to the Pre-screening Inclusion Criteria, for entry into the study:\n\n1. Participants must provide written consent in the IRB-approved or Ethics Committee (EC) approved informed consent form or have a legally authorized representative (LAR) provide written consent on the participant's behalf in accordance with local and national guidance and regulation;\n2. Participants must be willing to undergo an MRI brain scan within 90 days and an amyloid and tau PET scan within 120 days of signing informed consent;\n3. Participants must be willing to comply with all study procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;\n4. Fluency in the language of the tests used at the study site;\n5. Participants must be willing to be contacted for possible participation in clinical research trials once their participation in this study ends; and\n6. Participants must have a Mini-Mental State Exam (MMSE) score of 16 to 30 inclusive at screening.\n\nExclusion Criteria:\n\nPre-screening Exclusion Criteria\n\nParticipants who meet ANY of the following criteria will not be eligible to progress to Visit 1 (Screening):\n\n1. Participant is unable to undergo amyloid and tau PET scans due to self-reported pregnancy, sensitivity to ligands being used, poor venous access, contraindication to PET, or planned or recent exposure to ionizing radiation that in combination with the planned administration of amyloid radioligand would result in a cumulative exposure that exceeds recommended local guidelines;\n2. Participants who have reported or have a known negative amyloid PET scan in the past 6 months;\n3. Participants with any known contraindication to brain MRI scan;\n4. Participants with history of stroke or seizures within 1 year of the Pre-Screening Visit;\n5. Participants with history of cancer within the past 5 years with the exception of non-melanoma skin cancer or prostate cancer in situ;\n6. Participants with known or suspected alcohol or drug abuse or dependence within 1 year of the Pre- Screening Visit;\n7. Participants who report any current unstable psychiatric symptoms that could interfere with study procedures or impact study data (e.g., uncontrolled depression);\n8. Participants who have received any potential disease modifying AD treatment within 6 months prior to the Pre-screening Visit; and\n9. Participants with known history or self-report to be Human Immunodeficiency Virus (HIV) Positive unless controlled by antiviral medication.\n\nCore Study Exclusion Criteria\n\nParticipants who meet ANY of the following criteria, in addition to the Pre-screening Exclusion Criteria, will not be eligible to enroll into the study:\n\n1. Participants who, in the opinion of the Site Principal Investigator, have serious or unstable medical conditions that would prohibit their completion of all study procedures and data collection;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Participants with self-reported, untreated conditions such as vitamin B12 or folate deficiency or bladder infections that in the opinion of the Site Principal Investigator could contribute to cognitive impairment;\n4. Participants who have completed cognitive testing within 1 month of Visit 1 (Screening) where the Site Principal Investigator believes the participant's exposure may cause practice effect;\n5. Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Site Principal Investigator;\n6. Participants with a Geriatric Depression Scale (GDS) score greater than or equal to 8 at Visit 1 (Screening) and is deemed to be clinically significantly depressed by the Site Principal Investigator;\n7. Participants with a Rey Auditory Verbal Learning Test (RAVLT) t-score of ≥ 1.2 standard deviation above the mean. For non-African Americans, calculate age-sex-education adjusted t-scores. For African American participants, use the MOANS to calculate the age-education adjusted t-scores;\n8. Participants weighing less than 110 pounds;\n9. Participants who are direct employees or family members of direct employees of the participating investigators' sites;\n10. Participants who are direct employees of the Sponsor;\n11. Participants who, in the opinion of the investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity; and\n12. For participants completing the RetiSpec retinal scan: Those with a known history of contraindication or allergy to Tropicamide 1% (pupil dilation drop).\n\nLongitudinal Sub-Study Eligibility\n\nInclusion Criteria:\n\nParticipants must meet ALL of the following criteria for entry into the sub-study:\n\n1. Participants who completed the Bio-Hermes-002 Core Study;\n2. Are willing to complete phone call visits with site staff every three months and return to the clinic for an annual evaluation; and\n3. Are willing to complete annual PET scans for both amyloid and tau scans.\n\nExclusion Criteria:\n\nParticipants who meet ANY of the following criteria will not be eligible for entry into the sub-study:\n\n1. Those who are enrolled or intend to enroll into a clinical trial for Alzheimer's disease with a potential disease-modifying intervention;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Those who intend to use medications outside clinical research studies approved by regulatory authorities to modify Alzheimer's disease pathology.",{"count":636,"type":22},1200,"Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.",[67,26,639,640,641,642],"Alzheimer's Disease, Early Onset","Memory Loss","Memory Disorders","Memory Impairment",[26,639,67,644,645,640,641,642],"Older Volunteers","Healthy Volunteers","2026-04-13",{"date":648,"type":38},"2026-04-15",{"date":650,"type":38},"2024-09-26",{"date":652,"type":22},"2028-07",{"name":654,"class":78},"GAP Innovations, PBC"]